Add Yahoo as a preferred source to see more of our stories on Google. Eli Lilly will speak with regulators about the Phase III data. Image credit: luchschenF / Shutterstock.com (luchschenF / ...
Selpercatinib demonstrated a highly statistically significant and clinically meaningful improvement in reducing the risk of disease recurrence or death Results from the LIBRETTO-432 trial build on ...
Eli Lilly and Co. (NYSE:LLY) on Monday shared positive topline results from the Phase 3 LIBRETTO-432 clinical trial for ...
Traditional approval of encorafenib plus cetuximab and fluorouracil-based chemotherapy for patients with BRAF-mutated ...
Merck’s Keytruda will soon lose exclusivity, just as weight-loss giants Eli Lilly and Novo Nordisk press in with their blockbuster GLP-1s.
SGLT2 inhibitors showed significantly improved mortality benefits compared with DPP-4 inhibitors in patients with diabetic kidney disease (DKD) in a large target trial emulation study that adds ...
BeOne Medicines Q4 earnings and revenue beat the Street's expectations; the outlook missed by a small margin. Read why I have ...
Lilly's phase 3 LIBRETTO-432 trial of Retevmo an adjuvant therapy in early-stage RET fusion-positive lung cancer meets its primary endpoint: Indianapolis Tuesday, February 17, 202 ...
Background The epidemiology and long-term healthcare utilisation associated with chronic kidney disease (CKD) among those ...
The study result is the latest step forward for a drug Bristol could eventually pay more than $8 billion for and has spotlighted as important to its future growth.
The FDA has granted full approval to Pfizer Inc.’s Braftovi when used with Eli Lilly’s Erbitux (cetuximab) and fluorouracil‑based chemotherapy for adults with metastatic colorectal cancer carrying a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results